Retrospective evaluation of abdominal MRI imaging: prognostic value and therapy monitoring in patients with pancreatic neuroendocrine tumors receiving capecitabine and temozolomide (Cap/Tem) therapy

Recruiting

• Conditions: D44; D37.7; D47; Neoplasm of uncertain or unknown behaviour of endocrine glands; Other digestive organs; Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue

• Registration Number: DRKS00031783
• Lead Sponsor: MU München

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-09-18
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

> 18 years
- NET pancreas
- Abdominal MRI imaging before therapy and after Cap/Tem therapy, if applicable.
- Cap/Tem therapy

Exclusion Criteria

- < 18 years
- Incomplete examinations due to premature termination
- Limited image quality due to artifacts

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
In this retrospective study, MRI data of patients with neuroendocrine pancreatic tumors will be analyzed. The following MR parameters will be retrospectively collected and analyzed anonymously directly before the start of Cap/Tem therapy:<br>morphological criteria of the primarius, lymph node and liver metastases, such as size, vascularization, tumor burden and necrosis.

Secondary Outcome Measures

Name	Time	Method
Functional parameters of the primarius, lymph node and distant metastases. <br>Diffusion imaging<br>Qualitative: presence of diffusion restriction, <br>Quantitative: analysis of the primarius